Clinical Trial Update: A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on the safety and efficacy of EIK1001 in combination with pembrolizumab and chemotherapy for Stage 4 non-small cell lung cancer; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• EIK1001 (EIK1001)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Eikon Therapeutics | Conditions: Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING